Most Recent Stories
More NewsRocket Pharmaceuticals: Q2 Earnings Snapshot
![Bull & Bear - Bull on Wall Street](https://media.barchart.com/contributors-admin/common-images/images/Stocks%2C%20Markets%2C%20%26%20Global%20Economy/Bull%20%26%20Bear/Bull%20on%20Wall%20Street.jpg)
The S&P 500 Index ($SPX ) (SPY ) today is down -0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.29%. Stock indexes today are lower...
![Wall Street - shutterstock_244823071](https://media.barchart.com/contributors-admin/common-images/images/Stocks%2C%20Markets%2C%20%26%20Global%20Economy/Wall%20Street/shutterstock_244823071.jpg)
The S&P 500 Index ($SPX ) (SPY ) today is up +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.33%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.35%. Stock indexes today are moderately...
Rocket could launch its medicines sooner, but Intellia is aiming for larger markets.
Its near-term risks are subtle but bigger than their flying stock price might indicate.
![Healthcare - stethoscope-with-injection-protective-mask-lying-over-medical-chart-SBI-300904603](https://media.barchart.com/contributors-admin/common-images/images/Healthcare/stethoscope-with-injection-protective-mask-lying-over-medical-chart-SBI-300904603.jpg)
Although Rocket Pharmaceuticals lived up to its name on Wednesday due to an encouraging clinical trial development, the big dogs have some questions about RCKT stock.
The late-stage pharmaceutical company said it had reached an agreement with the Food and Drug Administration regarding a phase 2 trial for a Danon disease therapy.
![Wall Street - shutterstock_2269106477](https://media.barchart.com/contributors-admin/common-images/images/Stocks%2C%20Markets%2C%20%26%20Global%20Economy/Wall%20Street/shutterstock_2269106477.jpg)
September S&P 500 futures (ESU23) are down -0.02%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.04% this morning as market participants geared up for a key U.S. consumer inflation report...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...